- Home
- CPBI vs STTK Comparison
CPBI vs STTK Comparison
Compare CPBI & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPBI
- STTK
- Stock Information
- Founded
- CPBI 2023
- STTK 2016
- Country
- CPBI United States
- STTK United States
- Employees
- CPBI N/A
- STTK N/A
- Industry
- CPBI
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- CPBI
- STTK Health Care
- Exchange
- CPBI Nasdaq
- STTK Nasdaq
- Market Cap
- CPBI 56.2M
- STTK 56.8M
- IPO Year
- CPBI N/A
- STTK 2020
- Fundamental
- Price
- CPBI $14.50
- STTK $1.11
- Analyst Decision
- CPBI
- STTK Hold
- Analyst Count
- CPBI 0
- STTK 3
- Target Price
- CPBI N/A
- STTK $2.00
- AVG Volume (30 Days)
- CPBI 6.3K
- STTK 172.1K
- Earning Date
- CPBI 01-01-0001
- STTK 02-27-2025
- Dividend Yield
- CPBI N/A
- STTK N/A
- EPS Growth
- CPBI N/A
- STTK N/A
- EPS
- CPBI 0.89
- STTK N/A
- Revenue
- CPBI $18,262,000.00
- STTK $6,435,000.00
- Revenue This Year
- CPBI N/A
- STTK $313.04
- Revenue Next Year
- CPBI N/A
- STTK N/A
- P/E Ratio
- CPBI $16.21
- STTK N/A
- Revenue Growth
- CPBI 37.54
- STTK 382.75
- 52 Week Low
- CPBI $9.91
- STTK $0.94
- 52 Week High
- CPBI $15.50
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- CPBI 47.28
- STTK 44.36
- Support Level
- CPBI $14.50
- STTK $1.13
- Resistance Level
- CPBI $14.80
- STTK $1.22
- Average True Range (ATR)
- CPBI 0.37
- STTK 0.11
- MACD
- CPBI -0.05
- STTK -0.01
- Stochastic Oscillator
- CPBI 28.09
- STTK 15.15
About CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists primarily of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in our primary market area, as well as commercial real estate loans.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.